Clinical trials · New York
Allergy clinical trials in New York
We’re tracking 37 recruiting allergy studies with a site in New York — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT07768371RecruitingPhase 3
Remibrutinib for peanut, milk, or egg allergies
This study tests an investigational drug called remibrutinib to see if it can reduce allergic reactions to peanuts, milk, or eggs. It is for people aged 12 to 65 who have been diagnosed with a food allergy and are willing to participate in food challenges.
New York, New YorkAges 12–65 - NCT06260956Recruiting
Peanut and egg study for expecting mothers
This study looks at whether eating or avoiding peanuts and eggs during pregnancy can affect the baby's risk of allergies. You and your baby will be followed for a year after birth.
Rochester, New YorkAges 1 day+ - NCT06406114RecruitingPhase 2
Better Allergy Testing for Cephalosporin Antibiotics
This study tests better ways to diagnose allergies to common cephalosporin antibiotics, like Keflex and Rocephin. By participating, you may learn if you are truly allergic to these medicines and if they are safe for you to take in the future.
Rochester, New YorkAges 18–70 - NCT07279467Recruiting
Peanut allergy food challenge biomarker study
This study aims to identify markers in the blood that could help predict how severe a peanut allergy reaction might be. If you qualify, your child will undergo a supervised peanut challenge to see how their body responds.
New York, New YorkAges 1–17 - NCT07220811RecruitingPhase 2
Testing a new drug for food allergies
This trial tests a new medication called RPT904 in people with IgE-mediated food allergies to foods like peanut, milk, egg, cashew, or walnut. The goal is to see if it reduces allergic reactions when you eat a small amount of the food.
Great Neck, New YorkAges 12–55 - NCT07015996RecruitingPhase 2
Tezepelumab for peanut allergy oral immunotherapy
This trial tests whether adding tezepelumab (a biologic drug) to peanut oral immunotherapy can help people with peanut allergy better tolerate small amounts of peanut protein without having an allergic reaction.
New York, New YorkAges 12–55 - NCT07778459Recruiting
Liver transplant study for people with HIV
This study tests whether it's safe and effective for people with HIV to receive a liver transplant from a donor who also has HIV. It aims to expand access to transplants for people with HIV.
New York, New YorkAges 18 years+ - NCT07757802RecruitingPhase 1
HIV vaccine nanoparticle and mRNA booster for healthy adults
This study tests a new HIV vaccine that uses tiny particles (nanoparticles) and an mRNA booster — similar to some COVID vaccines. The goal is to see if it is safe and helps your body fight HIV. It's for healthy adults who do not have HIV.
Rochester, New YorkAges 18–55 - NCT07569029RecruitingPhase 1
HIV vaccine with treatment break to boost immune response
This Phase 1 trial tests two new HIV vaccines (DV700P-RNA and DV701B1.1-RNA) combined with a monitored break from HIV medications in people with well-controlled HIV. The goal is to see if this approach safely strengthens the immune system's ability to fight HIV.
New York, New YorkAges 18–60 - NCT07549503RecruitingPhase 2
Liver Transplant Immune Changes Study
This research study tracks early signs of immune system changes in children who received a liver transplant 3–7 years ago and are doing well. By studying blood and liver samples, researchers hope to better understand how to prevent rejection and improve long-term transplant survival.
New York, New YorkAges 3–13 - NCT07390474RecruitingPhase 1
HIV vaccine safety and immune response study for healthy adults
This study tests two experimental mRNA-based HIV vaccines to see if they are safe and create an immune response. It is for healthy adults aged 18 to 55 who do not have HIV.
New York, New YorkAges 18–55 - NCT07108387RecruitingPhase 2
Stopping or reducing tocilizumab for well-controlled giant cell arteritis
This study compares stopping tocilizumab (Actemra) completely versus reducing the dose in people whose giant cell arteritis has been well controlled for at least a year. The goal is to find out which approach keeps the disease in remission while reducing medication side effects.
Great Neck, New YorkAges 50 years+ - NCT07103746RecruitingPhase 2
Ublituximab for antibody-positive IMNM
This study tests an investigational medication called ublituximab (an infusion) for people with a rare autoimmune muscle disease called IMNM. It aims to reduce muscle weakness and damage by targeting specific immune cells (B cells). To join, you need a recent diagnosis (within 1 year), specific antibodies, and be on limited other medications.
Great Neck, New YorkAges 18 years+ - NCT07059091RecruitingPhase 2
Allergy medicine for COPD with indoor allergies
This study tests if omalizumab, an allergy medicine, can help people with COPD who are allergic to common indoor allergens and have had recent flare-ups. It aims to see if reducing allergic reactions can improve COPD control.
New York, New YorkAges 40 years+ - NCT07040319RecruitingPhase 1/Phase 2
Hepatitis C treatment study for pregnant women
This study tests a medicine called glecaprevir/pibrentasvir for pregnant women with hepatitis C, with or without HIV. It aims to see how the medicine works in the body and if it is safe during pregnancy.
The Bronx, New YorkAges 16–45 - NCT06919003RecruitingPhase 2
Improving kidney transplant with a single injection of a protective protein
This trial tests whether a single injection of C1 esterase inhibitor into a donated kidney during preservation can improve transplant outcomes. It is for adults on dialysis waiting for a deceased-donor kidney who meet specific blood and tissue matching requirements.
The Bronx, New YorkAges 18–75 - NCT06918990RecruitingPhase 1
CarBel for antibody-mediated rejection after kidney transplant
This study tests a new drug called CarBel to treat antibody-mediated rejection in kidney transplant patients. The goal is to see if it can help stop the rejection and protect your new kidney.
New York, New YorkAges 18–75 - NCT06908083Enrolling by invitationPhase 1
Stopping HIV treatment with antibody therapy
This trial tests whether a combination of powerful antibodies (bNAbs) can help control HIV after stopping standard HIV treatment. Participants will pause their daily HIV medications while receiving these antibodies, and doctors will closely monitor their immune system and virus levels. It's for people who are already well-controlled on HIV treatment and have participated in a specific earlier study.
New York, New YorkAges 18–70 - NCT06796686RecruitingPhase 1
HIV vaccine safety and immune response study for healthy adults
This trial tests a new two-part HIV vaccine regimen in healthy adults without HIV. The goal is to see if it is safe and produces an immune response that could help prevent HIV.
New York, New YorkAges 18–55 - NCT06665646RecruitingPhase 1
HIV vaccine booster study for previous trial participants
This study tests a booster vaccine for HIV in people who were part of an earlier HIV vaccine trial. The goal is to see if it's safe and helps the immune system fight HIV better.
New York, New YorkAges 18–60 - NCT06517693RecruitingPhase 1
HIV antibody safety study for newborns at risk
This study tests whether giving a combination of two lab-made antibodies (PGT121.414.LS and VRC07-523LS) to newborns exposed to HIV during pregnancy is safe and how the body processes them. It may help protect infants from getting HIV after birth.
The Bronx, New YorkAges Up to 3 days - NCT06504160RecruitingPhase 1
Testing a bacteria cream for eczema (TIME-2)
This study tests whether a cream made from a friendly skin bacteria (Staphylococcus hominis) can help treat eczema. Eligible participants will apply the cream to eczema patches on their arms, legs, or trunk for several weeks.
New York, New YorkAges 6 years+ - NCT06478017RecruitingPhase 2
Belatacept for heart transplant recipients
This study tests a drug called belatacept, which may help prevent the body from rejecting a new heart. It is given after a heart transplant, and the goal is to see if it works as well as or better than standard anti-rejection medicines.
New York, New YorkAges 18–76 - NCT06476132RecruitingPhase 2
Belumosudil for lung transplant patients at risk of chronic rejection
This trial tests whether the drug Belumosudil can help prevent chronic lung rejection in people who recently had a lung transplant and showed signs of early rejection. It may improve long-term lung health.
New York, New YorkAges 12 years+
Allergy trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting allergy studies listed above.
- Columbia University Irving Medical Center · 2 studies
- Icahn School of Medicine at Mount Sinai / Mount Sinai Hospital · 2 studies
- Icahn School of Medicine at Mount Sinai: Department of Pediatrics Allergy & Immunology · 2 studies
- Montefiore Medical Center · 2 studies
- Northwell Health · 2 studies
- Northwell Health: Division of Rheumatology and Allergy-Clinical Immunology · 2 studies
- NYU Langone Health (Site # 71177) · 2 studies
- Bronx-Lebanon Hospital Center
What taking part in a allergy study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Allergy trials in other states
Common questions
- Are there allergy clinical trials in New York?
- Yes. We're currently tracking 37 recruiting allergy studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a allergy study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a allergy trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New allergy studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.